Hoppu K
Children's Hospital, Helsinki, Finland.
Arch Dis Child. 1989 Mar;64(3):343-5. doi: 10.1136/adc.64.3.343.
The pharmacokinetics of trimethoprim administered orally or intravenously were investigated in six infants aged 1.7 months to 1.1 years. In these infants trimethoprim had a mean half life of 4.6 hours; this was comparable with the values found in young and school age children (3.8 and 5.4 hours respectively) and about a quarter of the half life in newborns. The volume of distribution (1.5 l/kg) was smaller than in newborns but larger than in young or school age children (0.9 and 1.1 l/kg respectively). The plasma clearance in these infants (3-3 ml/min/kg) was slightly larger than in newborns or in either group of older children (2.9 and 2.4 ml/min/kg respectively). Thus the most dramatic changes in trimethoprim pharmacokinetics seem to occur during the first two months of life. A reduced daily dose of trimethoprim is necessary during the first two months only. An increased daily dose, by addition of a third dose each day, is recommended from two months.
对6名年龄在1.7个月至1.1岁的婴儿进行了口服或静脉注射甲氧苄啶的药代动力学研究。在这些婴儿中,甲氧苄啶的平均半衰期为4.6小时;这与在幼儿和学龄儿童中发现的值相当(分别为3.8小时和5.4小时),约为新生儿半衰期的四分之一。分布容积(1.5升/千克)小于新生儿,但大于幼儿或学龄儿童(分别为0.9升/千克和1.1升/千克)。这些婴儿的血浆清除率(3-3毫升/分钟/千克)略高于新生儿或两组大龄儿童(分别为2.9毫升/分钟/千克和2.4毫升/分钟/千克)。因此,甲氧苄啶药代动力学最显著的变化似乎发生在生命的头两个月。仅在头两个月需要减少甲氧苄啶的每日剂量。建议从两个月起增加每日剂量,即每天增加第三剂。